Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy [PDF]
Global & Regional Health Technology Assessment, 2021 Purpose: The objective of this analysis was to compare the cost per responder between risankizumab and secukinumab among patients with moderate-to-severe plaque psoriasis in Italy.
Paolo Gisondi +3 more
doaj +3 more sources
Costo per responder del metotrexato rispetto ad altre terapie in pazienti con psoriasi a placche da moderata a grave in Italia. [PDF]
Glob Reg Health Technol Assess, 2022 Cost per responder for methotrexate versus other therapies in patients with moderate-to-severe plaque psoriasis in Italy Objective: Conventional synthetic disease modifying antirheumatic drugs (csDMARDs) were recommended in 2019 as first line therapy ...
Pompilio G, Integlia D.
europepmc +2 more sources
Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs. [PDF]
Dermatol Ther, 2022 Abstract Adalimumab is the only biological drug approved to date for the treatment of moderate and/or severe hidradenitis suppurativa. Adverse events reported during therapy include paradoxical psoriasiform reactions. No guidelines are currently available for the management of this clinical condition.
Burzi L +5 more
europepmc +2 more sources
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis) [PDF]
Frontiers in Immunology, 2023 IntroductionThe development of several effective biological drugs for moderate-to-severe plaque psoriasis has dramatically changed the lives of patients.
Luigi Gargiulo +26 more
doaj +2 more sources
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis). [PDF]
J Eur Acad Dermatol Venereol, 2023 Abstract Background Tildrakizumab is a humanized monoclonal antibody that binds selectively the p19 subunit of interleukin‐23. It is approved for treatment of moderate–severe chronic plaque psoriasis. Objectives We conducted a 52‐week retrospective study to assess the effectiveness and safety of tildrakizumab in a real‐life setting.
Narcisi A +19 more
europepmc +2 more sources
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis) [PDF]
Frontiers in Medicine, 2023 IntroductionBrodalumab is a monoclonal antibody that targets the subunit A of the interleukin-17A receptor (IL17RA), inhibiting the signaling of various isoforms of the IL-17 family.
Luigi Gargiulo +28 more
doaj +2 more sources
Artificial intelligence processing electronic health records to identify commonalities and comorbidities cluster at Immuno Center Humanitas. [PDF]
Clin Transl Allergy, 2022 Abstract Background Comorbidities are common in chronic inflammatory conditions, requiring multidisciplinary treatment approach. Understanding the link between a single disease and its comorbidities is important for appropriate treatment and management.
Morandini P +10 more
europepmc +2 more sources
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy [PDF]
Patient Preference and Adherence, 2021 Giuseppe Argenziano,1,* Paolo Amerio,2 Maria Grazia Aragone,3 Ginevra Baggini,4 Manuela Baldari,5 Gianpiero Castelli,6 Simmaco Coppola,7 Antonio Costanzo,8,9 Rocco De Pasquale,10 Maria Concetta Fargnoli,11 Caterina Foti,12 Claudia Giofrè,13 Serena
Argenziano G +22 more
doaj +2 more sources
The Oxidative Stress-Induced miR-200c Is Upregulated in Psoriasis and Correlates with Disease Severity and Determinants of Cardiovascular Risk. [PDF]
Oxid Med Cell Longev, 2019 Psoriasis is a chronic inflammatory skin disease associated with reactive oxygen species (ROS) increase and a higher risk of cardiovascular (CV) events. We previously showed that the miR‐200 family (miR‐200s) is induced by ROS, miR‐200c being the most upregulated member responsible for apoptosis, senescence, ROS increase, and nitric oxide decrease ...
Magenta A +12 more
europepmc +2 more sources